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Summary.-Adriamycin (10 mg/kg) administered s.c. to male ACI rats bearing
Hepatoma H-4-1I-E caused a 9-day delay in tumour growth but no changes in the
clonogenic fraction of the tumour were detectable by in vitro assay at any time after
treatment. There is no significant decrease in the yield of cells on enzymatic
dissociation of the tumour nor a reduction in mg DNA/g tumour that might indicate
a decrease in tumour cellularity. Mitotic and labelling indices and [3H]dT uptake
into DNA remain essentially unchanged, relative to age-equivalent controls, but are
slightly lower than in controls of equal weight. The reliability of the clonogenic
assay and possible mechanisms by which Adriamycin delays tumour growth are
discussed.
ADRIAMYCIN (ADR) is found in associa-
tion with the nucleoprotein of the treated
cell (Calendi et al., 1965) possibly bound
to the DNA (DiMarco, 1975). In vitro,
ADR causes DNA single- and double-
strand breaks (Byfield et al., 1977),
chromosome damage (Hittelman & Rao,
1975), inhibits synthesis of RNA and
DNA (Kim & Kim, 1972; Clarkson &
Humphrey, 1977), possibly by inhibition
ofthe respective polymerases (Wang et al.,
1972). Many of these effects result in cell
death.
ADR kills cells in vitro both in plateau
phase and throughout the cell cycle of
actively reproducing cells (Barranco,
1975), though most efficiently in mitosis
and early S phase: CHO (Barranco, 1975),
HeLa (Kim & Kim, 1972). With respect
to cell-cycle progression, 0-1 ,tg/ml ADR
delays CHO cells through S and G2
(Hittelman & Rao, 1975; Kimler &
Leeper, 1976; Gohde et al., 1979). Delay
in progression of CHO cells from G1 into S
was recorded by Barranco (1975) using a
continuous exposure to 0 5 [kg/ml, and
Gohde et al. (1979) using a 30min pulse of
1.0 [kg/ml, but not by Hittelman & Rao
(1975) using 0 5 jug/ml continuously.
The action of ADR in vivo is not well
understood. Wang et al. (1972) did not
detect inhibition of nucleic acid polymer-
ases, but did detect inhibition of RNA
and DNA synthesis in LI2120 cells grown
as an ascitic tumour. Grdina (1979) found
synchronous S-phase fibrosarcoma cells
most susceptible to ADR killing (10 mg/
kg) when lodged in the mouse lung, using
the lung-colony assay system. Cell killing
in solid tumours may be size-dependent
(EMT6/VJ/AC, Twentyman & Bleehen,
1976), smallest tumours being most sen-
sitive. There is now evidence that ADR
may cause an appreciable delay in tumour
growth without a detectable cell kill in
some experimental tumours (Rowley et al.,
1979; Dethlefsen et al., 1979). Micro-
spectrophotometric (Rowley et al., 1979)
and FMF data (Dethlefsen et al., 1979)
suggest that growth delay may be due
rather to delayed tumour cell-cycle pro-
gression.
The present paper reports additional
data obtained in attempts to find cell-
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kinetic and compositional changes in
Hepatoma H-4-11-E which might explain
the appreciable tumour growth delay
without detectable cell kill found after
in vivo treatment with ADR.
MATERIALS AND METHODS
Animals and tumours
Hepatoma H-4-IJ-E cells were maintained
in vitro in Swim's medium plus 25% serum
(20% horse, 5% foetal bovine; GIBCO, New
York). Cells were passaged weekly on attain-
ing confluence. In vitro growth characteris-
tics are detailed in Kovacs et al. (1977).
Tumours were raised by s.c. inoculation of
2x 106 log-phase cells in 0-1 ml serum-free
medium into the flank of male ACI rats
(Laboratory Supply Co., Indianapolis, IN).
Rat weight at inoculation was 120-140 g.
Animals were caged individually in an air-
conditioned room lighted from 08:00 to
20:00. Rat chow (Charles River Labora-
tories, Wilmington, MA) and water were
provided ad libitum.
Drug
Adriamycin (ADR) was supplied by the
Drug Synthesis and Chemistry Branch,
Division of Cancer Treatment, National
Cancer Institute. It was dissolved in 0.9%
NaCl solution and administered s.c. for doses
of 10 mg/kg (60 mg/M2) or i.p. for larger
doses.
Tumour assays
Volume.-Tumour volumes were calculated
from measurements of length, width, and
height on the assumption that the tumours
were hemi-ellipsoids where volume=4/3 vT
1/2.w/2.h/2. This formula reduces to 1/2
lwh. Measurements were made daily for
2-4 days before treatment and 3-5 times
weekly subsequently. Treatments were given
when individual tumour volumes first ex-
ceeded 200 mm3. Time to grow to the end-
point volume (i.e., the volume to which
growth delay is measured) was determined
for each tumour and the values averaged
for each group. Growth delay was calculated
as the mean time for treated tumours to
reach the end point volume minus the mean
timefor control tumours toreachthatvolume.
The growth delay s.e. was calculated by the
formula,,/AT2+ AC2, where AC is the s.e. of
the mean time for untreated tumours to
reach the endpoint volume and AT the
corresponding value for treated tumours.
The dose-response curve for tumour-
growth delay was compiled using data from
several experiments, the data ofone ofwhich
are presented in Rowley et al. (1979), viz.,
the tumour volume response to 10 mg/kg
ADR.
Clonogenicity.-Tumours were resected
from ether-killed rats, weighed and minced
with scalpels. About 1 g of thoroughly
mixed tumour mince was suspended in
37°C citrate-buffered 0.25% trypsin solu-
tion (DIFCO, activity 1: 250), and magneti-
cally stirred for 15 min. Tumour debris was
filtered off with gauze and an equal volume
of serum medium added to the remaining
suspension to neutralize the trypsin. The
suspension was then centrifuged and the
cells resuspended in serum medium. Cell
counts were made by haemacytometer, and
all cells were included except lymphocytes;
other host cells, presumed to be present,
were indistinguishable from tumour cells.
Appropriate dilutions were made for plating
in 10cm Petri dishes. The number of clones
containing >50 cells was determined after
10 day's incubation. The proportions of
clone-forming cells in treated tumour-cell
suspensions are expressed as a fraction of
the untreated tumour-plating efficiency.
Analysis of DNA content and specific
activity.-One hour before being killed the
ratsweregiven 50,Ci of thymidine-(methyl)-
3H, sp. act. 3 Ci/mmol, i.p. A sample of the
tumour was treated to eliminate RNA and
extract DNA, as detailed in Hopkins et at.
(1978) and the DNA/g tumour measured by
the method of Burton (1956). Calf thymus
DNA was the standard. Radioactivity in the
nucleic-acid extracts was measured on a
Beckman liquid-scintillation spectrophoto-
meter with external standardization.
Light microscopy of tissue sections.-Tissue
specimens of [3H]dT-labelled tumours were
fixed in neutral formalin, embedded in
paraffin wax, sectioned and stained by the
Feulgen reaction. Slides were dipped in
Kodak NTB2 emulsion for autoradiography,
exposed for 3-5 weeks, and developed in
Kodak D-19. The percentage of mitotic
figures and nuclei bearing >8 grains was
scored from random traverses of the section.
The grain-count threshold for nuclei to be
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scored as labelled was determined by plot-
ting grains per nucleus against labelling
index (LI) and the break point in the curve
indicated the threshold.
RESULTS
Tumour growth after ADR treatment
was measured for doses up to 10 mg/kg
only (LD10/30, Hopkins et al., 1978), as
drug toxicity was excessive at higher
doses. Drug-induced reduction of animal
longevity also narrowly restricted the
choice of endpoint volume for the deter-
mination of delay. A volume of 8 x Vo
was selected as the smallest on the
portion of the tumour-volume curves
where growth rates parallel those of
untreated tumours.
Delay was dose-dependent over the
range measured (Fig. 1); 10 mg/kg ADR
produced a delay of 9 days.
The inability to demonstrate cell kill in
Tumour H-4-11-E after treatment of rats
with 10 mg/kg ADR, has been previously
reported (Rowley et al., 1979) and is
illustrated in Fig. 2 left axis. No cell kill
was detectable at any time up to 16 days
after treatment when cell viability was
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FIG. 1.-Mean tumour growth delays (10
animals per point) resulting from s.c.
administration of ADR to rats bearing
Tumour H-4-II-E. Bars on this and all
other figures represent +s.e.
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FIG. 2.-Clonogenic fraction of H-4-II-E
tumours assayed at intervals after 10
mg/kg ADR (a). Cell yield by enzymatic
dissociation of untreated tumours (LOI)
and from tumours dissociated at intervals
after 10 mg/kg ADR (0). Each point
basedon 3 ratsfrom 3 separateexperiments.
(Some data points for clonogenic fraction
were previously published in Rowley et al.,
1979 Reprinted with permission. Copyright
1979, Pergamon Press, Ltd).
assayed by in vitro plating of cells taken
from resected and dissociated tumour
treated in vivo. The cell yield (Fig. 2,
right axis) for the dissociation process
was 2-5 x107/g for untreated tumours
and was not significantly altered by ADR
treatment until Day 8.
DNA/g tumour tissue was also un-
changed by treatment, whether compari-
son is made to age- (Fig. 3a) or weight-
equivalent (Fig. 3b) controls. As this
parameter is a measure of cellularity, this
supports the results of the dissociation
procedure.
The influence of changes in proportions
of tissue components (stroma to paren-
chyma and viable to necrotic) is not
known, and cannot be established without
a careful morphometric analysis. No
obvious changes were noted, however,
either as a result of treatment (Betsill,
personal communication) or as a function
oftumour size (Rowley et al., 1980).
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Fig. 3. (a) Changes in DNA concentration
of H-4-1I-E tumours with time after treat-
ment. 0 controls (untreated tumours of
comparable volume on day of treatment);
* 10 mg/kg ADR. (b) Relationship
between DNA concentration and weight
of individual H-4-1I-E tumours at resec-
tion 0 control; 10 mg/kg ADR.
Cell killing could only be detected by
the clonogenic assay after ADR doses
above 25 mg/kg, 24 h after administration
(Fig. 4). Dq for this curve is <4c25 mg/kg
and Do i:-80 mg/kg. No killing was
detected at 1 h, making it unlikely that
drug carry-over to the culture dish
contributed to the killing observed after
1 day. To produce the dose-response
curve, ADR was injected i.p., since the
volumes of drug used were too large to
administer s.c. This route of administra-
tion did not appear to alter the tumour-
growth delay incurred by 10 mg/kg, but
did decrease animal survival, by increasing
the severity and frequency of gut compli-
cations (usually adhesions).
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F'IG. 4.-Changes in clonogenic fraction of
Tumour H-4-II-E with ADR dose. Assays
performed at I h (O) or 24 h (*) after
i.p. administration of the drug.
The tumour LI was determined from
Feulgen-stained sections. LI fell with
tumour age (time after reaching treatment
volume) in untreated tumours. After
treatment, the LI was perhaps slightly
lower than in untreated tumours of the
same age on Days 1, 2 and 3 (Fig. 5a).
The relationship between individual
values of LI and tumour weight is pre-
sented in Fig. 5b. Tumour weights have
been logged merely to facilitate presenta-
tion and not to imply a particular depen-
dence. The line given was fitted by re-
gression analysis (r = 0.56); the thin dashed
curves represent the 9500 confidence
limits. Most treated tumour points lie
below the control line; more lie below the
confidence limits (18) than above them (2).
The data suggest that ADR chronically
reduced the proportion of cells able to
pass through the S phase of the cell cycle.
The rate of incorporation of [3H]dT
into tumour DNA was not significantly
altered by treatment, relative either to
age- or weight-equivalent controls (Fig. 6).
As a further check for cell-cycle perturba-
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FIG. 5. (a) Changes in labelling index of
H-4-II-E tumours with time after treat-
ment. Two separate experiments are shown
(circles and squares). 0, 0I untreated
tumours; 0, * 10 mg/kg ADR. (b)
Relationship between H-4-1I-E tumour
labelling index and tumour weights at
resection of individual tumours. Data from
2 experiments are presented (circles and
squares). Tumour weights have been
normalized to the mean weight of those
tumours sampled on the day of treatment
to allow statistical analysis. The heavy line
is the best fit to the untreated tumour
points for both experiments. The light lines
are the 95% confidence limits for that
curve. 0, untreated tumours; *
10 mg/kg ADR.
tions, grain counts per nucleus were made
in autoradiographs of [3H]dT labelled
tumours sampled on Days 1, 4, 9 and 14
after ADR treatment. Lls + s.e. were:
Day 1, 10-9+3-7 (controls= 36-15+ 3-15);
Day 4, 40O38 + 3 50; Day 9, 43-48 + 3 70
and Day 14, 34O00 + 3-24. Incorporation
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FIG. 6.-(a) Relative changes in [3H]dT
incorporation into H-4-II-E tumour DNA
at intervals after ADR administration.
0 controls; 0 10 mg/kg ADR. (b)
Relationship between [3H]dT incorporation
into H-4-II-E tumour DNA and tumour
weight at resection for individual tumours.
0 controls; 0 10 mg/kg ADR.
Days after Adriamycin
FIG. 7.-Mitotic index of H-4-II-E tumours
at intervals after ADR treatment. Two
experiments are presented (circles and
squares) 0, 0, untreated tumours; 0,
* 10 mg/kg ADR.
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FIG. 8.-Each curve represents the calculated
range of values of cell-cycle length and
growth fraction that, at the cell loss rate
(o=02-09), produce a tumour doubling
time of 257 h. The lightly shaded area is
defined by the values of any 2 of the 3
variables, the third being held constant at
the level observed in untreated tumours.
The dark shaded area encompasses values
that are compatible with the observations
(see text for full explanation).
was depressed on Day 1 according to this
assay.
The mitotic index (Fig. 7) showed a
slight and possibly non-significant de-
pression over the first week which did not
correspond to changes in LI. One possible
reason for this was indicated by the
presence in early tumour samples of a few
labelled prophase-like cells. Since G2 is
2 h long (Evans & Kovacs, 1977) and
[3H]dT was administered 1 h before killing
treatment either extended S towards
mitosis, initiated unscheduled DNA repli-
cation or promoted premature chromatin
condensation. Only the last would produce
erroneously high mitotic indices.
DISCUSSION
10 mg/kg ADR, administered to tumour-
bearing male ACI rats, produced a 9-day
delay in tumour growth, but no detectable
cell kill at any time up to 16 days after
treatment (Rowley et al., 1979). No
immediate changes in the cell yield of the
tumour-dissociation process or in tumour
cellularity were observed. Artificially high
cell-survival estimates, due to rapid clear-
ance of sterilized cells, are unlikely. As
further evidence against this artefact,
doses of ADR (50 and 100 mg/kg), which
reduced cell survival by 24 h after treat-
ment, did not cause detectable cell killing
when assayed 1 h after treatment, sug-
gesting no immediate cell killing.
We believe it unlikely that the tumour-
dissociation procedure selected only cells
that were resistant to ADR. On the
basis only of the duration of growth
delay after 10 mg/kg ADR (9 days or
4.4 tumour doublings), a reduction in the
proportion of surviving cells to 0 05
would be expected. The dissociation
procedure yields 10% of the cells
available (yield-2-5 x 107 cells/g tumour;
cellularity= 2-3 x 108 cells/g as assessed
from the DNA content per cell and per
gram of tumour, Hopkins unpublished)
the PE of these cells is 0'3 i.e. 0'03 of the
total number of tumour cells per gram is
clonogenic. Thus, to postulate that the
dissociation/plating procedure selects only
those cells that are unaffected by ADR
would require that >3 out of every 5
clonogenic cells remaining after treatment
be recovered by dissociation. This appears
improbable. In addition, the clonogenic
assay as used here detects radiation
cell-killing (Rowley et al., 1980). Since the
same factors may influence cell sensitivity
to either agent in vivo (viz. hypoxia,
proliferative activity and cell-cell asso-
ciation (Martin & McNally, 1979, 1980))
it also seems unlikely that the clonogenic
cells demonstrably sensitive to radiation
should be those resistant to ADR. This
subject is returned to below. In vitro,
H-4-II-E cells are quite susceptible to
ADR treatment (Do-4.5 ,ug/ml, Looney
et al., 1977).
Comparison can be usefully made with
the effects of radiation on this tumour
(Rowley et al., 1980). 15 Gy of 250 kVp
X-rays produced a similar growth delay
to 10 mg/kg ADR: 9 days. The clonogenic
fraction was reduced to 0 03, recovering
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exponentially to unity in 10 days. This
was accompanied by a reduction in cell
yield by the tumour-dissociation process
and in tumour cellularity (mg DNA/g
tumour) and by depression of LI, mitotic
index and [3H]dT uptake for 7 days after
irradiation. In short, none of the cell-
kinetic changes that accompany cell
killing by irradiation are seen after
exposure to ADR, while the growth
delays are comparable. It is therefore
probable that the apparent lack of ADR
cell killing at 10 mg/kg is real.
These data admit of 4 alternative
explanations that may operate singly or
in concert to account for the observed
growth delay:
(1) ADR incurs a cell-cycle delay (of
considerable duration) as indicated by
changes in LI.
(2) ADR chronically reduces the growth
fraction of the tumour which may be
brought about by drug action on the
tumour cell or tumour vasculature.
(3) ADR chronically increases the rate of
cell loss; i.e., compared with the
untreated tumour, a higher proportion
of the progeny of each cell division
fails to go on to reproduce and is
removed from the tumour.
(4) ADR alters the relationship between
tumour and host, retarding growth.
Steel (1977) has proposed the following
formula for changes in tumour cell-cycle
kinetics:
Td log 2
Tc (1-0). log (GF+1)
Steel's formula and the unperturbed
tumour-cell kinetics derived by Evans &
Kovacs (1977) can be used to calculate
the magnitude by which the length of the
tumour cell cycle (T,), the rate of the cell
loss (0), or the growth fraction (GF)
must be altered to produce the observed
retardationintumourgrowth. The tumour-
volume doubling time (Td) was 257 h
after ADR treatment, as calculated from
a log-linear fit (r=0-977) to the volume
data (Rowley et al., 1979) for points 2-12
days after 10 mg/kg ADR. In the un-
treated tumour (volume= 1380 mm3) Td
=49-2h, GF=U100, o=0 32 and T.=
39-1 h.
The results ofthis analysis are presented
graphically in Fig. 8. Each curve repre-
sents the range of combinations of GF and
Tc that will give a tumour-volume
doubling time of 257 h, when the cell loss
rate is that stated for that curve. The
boundaries AB, BC and AC represent the
values derived for any two parameters
with the third held constant at the value
observed in the untreated tumour, i.e., if
the cell loss rate is assumed to be un-
changed at 0-32, the line AB gives the
range of combinations of Tc and GF that
result in a Td of 257 h. The densely
shaded area encompasses the values of Tc
and GF that are compatible with the
maximum observed depression of tumour
LI (50%o, Days 1 and 2, Fig. 5a) suggesting
that any mechanism for growth delay
based on this analysis clearly must
include a large increase in cell loss rate
(>0.7). It is also possible that ADR
treatment induces a reduced rate of
progression through S phase, when an
increase in cell-cycle length would not
necessitate a reduction in LI. [3H]dT
incorporation measured in isolated DNA
(Fig. 6) is not reduced, and therefore does
not support this suggestion. While this
analysis is simplistic, it does indicate that
the observed slowing of tumour growth
after 10 mg/kg of ADR is not attributable
to a cell-cycle effect alone.
The response to ADR ofTumour 3924A,
a transplantable hepatoma grown s.c. in
the female ACI rat, is similar in several
respects to that of H-4-II-E (Hopkins
et al., 1978). 60 mg/M2 (10 mg/kg) ADR
gave a 5-day growth delay. No cell-
viability data are available, since this
tumour does not currently grow in vitro,
but mg DNA/g tumour tissue (cellularity)
was completely unaffected for up to 22
days after treatment. Both the [3H]dT
LI and the sp. act. of [3H]dT in extracted
DNA were slightly depressed for 9 days,
but by no more than 3000. No change in
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tumour histology (necrosis or fibrosis) was
detectable. Again, the cause of delayed
tumour growth was not clear, though
acute cell killing seemed improbable.
Dethlefsen et al. (1979) reported that
10 mg/kg ADR, administered to mice
bearing Tumour S102F, caused - 4 days'
growth delay, depressed [3H]dT incorpora-
tion into tumour DNA for 96 h and
lowered the cell LI and MI to - 25% and
- 12-5%, respectively, for more than 96 h.
Flow-cytometric analysis of dissociated,
treated tumour, interpreted with the aid
of a mathematical model of tumour
response, led to the conclusion that
tumour-growth delay was almost entirely
due to extended cell-cycle delay, pre-
dominately in G1 but also in G2. There
was "no evidence of cytotoxicity, as
evidenced by tumour regression, even at
doses of 20 mg ADR/kg body weight."
By contrast, growth delays in murine
Tumours EMT6/Ro after 11 mg/kg and
KHT after 13 mg/kg ADR could be
entirely accounted for by cell killing
(Siemann & Sutherland, 1980); delays
were of about one doubling time (4-5 or
2 days, respectively) and were associated
with halving of tumour-cell survival.
Notably, cell survival derceased with
time after ADR treatment to a nadir for
clonogenic fraction at 96 h or for clono-
genic cells per tumour at 72 h. This
agrees with our own observation after
high doses of ADR (Fig. 3). In the rat
mammary tumour 13762, 5 mg/kg ADR
caused no significant growth delay, but
LI was reduced by - 50%, and the
primer-available DNA-dependent DNA
polymerase labelling index andthe passage
of cells from S into G2 were lowered for
4 days (Braunschweiger et al., 1980).
Evidently the response of H-4-II-E is less
clear cut. Whilst undetected cell killing
must remain a possible cause of growth
delay, the large and distinct drug-induced
perturbations to tumour-cell proliferation
cited elsewhere were absent or more
subtle in H-4-II-E.
In summary, we have been unable to
correlate changes in cell viability, cellu-
larity or cell-cycle kinetics of the tumour
after ADR treatment (10 mg/kg) with
delayed tumour growth. Comparisons with
the effects of ADR on other rodent
tumours, and simple calculations of ex-
pected changes in cell kinetics, do not
indicate that cell-cycle delay or change in
growth fraction is a cause ofgrowth delay.
We tentatively suggest that an increase
in cell loss or some unknown modification
of the relationship between tumour and
host may be responsible. This effect
would probably be secondary to the
initial toxic action ofthe drug, as indicated
by the duration of growth retardation.
Growth does not recover to control rates
until 13-14 days after treatment, whereas
the half-life of residual ADR in a murine
tumour, EMT6, is 60 h (Siemanns &
Sutherland, 1979, 1980). Impaired vascu-
lar function is an example of damage that
might cause such a chronic reduction in
growth rate.
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